About
CardioScale provides on-site deterioration prediction for trauma victims. The companys solution helps save lives by enabling better triage and improved treatment prioritization decisions via its proprietary algorithm and portable cuff monitor, DTR8. CardioScale holds a worldwide patent for early shock diagnostics with a ready-to-use field monitor that measures all vital signs in addition to a proprietary cardiovascular reserve index (CVRI) to detect shock and preshock deterioration. The DTR8 measurement procedure is similar to that of a blood pressure test and provides comprehensive results in under 60 seconds. Measured indices are then calculated automatically using patented CVRI technology, and the results are transmitted wirelessly to a handheld device for review as well as displayed on the device itself. This numeric data can be used to evaluate the patients current condition as well as to provide a baseline for follow-up tests.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is CardioScale's primary focus?
- CardioScale focuses on providing on-site deterioration prediction for trauma victims to improve triage and treatment prioritization.
- What is the status of CardioScale as of November 2025?
- CardioScale ceased to operate in November 2025, and its status is inactive.
- When was CardioScale founded and where is it headquartered?
- CardioScale was founded in February 2012 and is headquartered in Ganei Tikva, Israel.
- What is CardioScale's flagship product?
- CardioScale's flagship product is the DTR8, a portable cuff monitor that measures vital signs and a proprietary cardiovascular reserve index (CVRI) for early shock diagnostics.
- Has CardioScale received any grants?
- In July 2018, CardioScale received a grant of $100,000 from the IIA (Israel Innovation Authority).
- What is the total amount of funding CardioScale has raised?
- CardioScale has raised a total of $100,000, which came from a grant.
- Does CardioScale hold any patents?
- Yes, CardioScale holds a worldwide patent for early shock diagnostics.
- When did CardioScale's Cardiovascular Reserve Index (CVRI) calculator receive CE Mark approval?
- CardioScale's Cardiovascular Reserve Index (CVRI) calculator received CE Mark approval in October 2019.
- Who are the founders of CardioScale?
- The founders of CardioScale are Maoz Ben-Ari and Uri Gabbay.
- What is the employee count for CardioScale?
- CardioScale has an employee count in the range of 1-10.